AI assistant
Elicio Therapeutics, Inc. — Director's Dealing 2021
Nov 18, 2021
33784_dirs_2021-11-17_b3a62cb1-12b6-4865-a321-f0c968e80fc1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Angion Biomedica Corp. (ANGN)
CIK: 0001601485
Period of Report: 2021-06-24
Reporting Person: Goldberg Itzhak (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-24 | Common Stock | F | 47410 | $13.78 | Disposed | 2020068 | Direct |
| 2021-11-15 | Common Stock | S | 111505 | $4.1724 | Disposed | 1908563 | Direct |
| 2021-11-16 | Common Stock | S | 38495 | $4.2553 | Disposed | 1870068 | Direct |
Footnotes
F1: The shares were withheld to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs").
F2: The shares reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2021 by the Reporting Person
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.48 inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.21 to $4.38 inclusive.